These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20694075)
1. Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton KA Core Evid; 2010 Jun; 4():191-8. PubMed ID: 20694075 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682 [TBL] [Abstract][Full Text] [Related]
10. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Gordon EM; Sankhala KK; Chawla N; Chawla SP Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989 [TBL] [Abstract][Full Text] [Related]
11. The Role of Trabectedin in Soft Tissue Sarcoma. Nakamura T; Sudo A Front Pharmacol; 2022; 13():777872. PubMed ID: 35281940 [No Abstract] [Full Text] [Related]
12. Trabectedin in soft tissue sarcomas. Petek BJ; Loggers ET; Pollack SM; Jones RL Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274 [TBL] [Abstract][Full Text] [Related]
13. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT; Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of trabectedin for the treatment of liposarcoma. Zijoo R; von Mehren M Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729 [TBL] [Abstract][Full Text] [Related]
15. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? Le Cesne A Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726 [TBL] [Abstract][Full Text] [Related]
16. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Carter NJ; Keam SJ Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287 [TBL] [Abstract][Full Text] [Related]
17. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040 [TBL] [Abstract][Full Text] [Related]
18. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671 [TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin. Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944 [TBL] [Abstract][Full Text] [Related]
20. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Le Cesne A; Blay JY; Cupissol D; Italiano A; Delcambre C; Penel N; Isambert N; Chevreau C; Bompas E; Bertucci F; Chaigneau L; Piperno-Neumann S; Salas S; Rios M; Guillemet C; Bay JO; Ray-Coquard I; Haddag L; Bonastre J; Kapso R; Fraslin A; Bouvet N; Mir O; Foulon S Ann Oncol; 2021 Aug; 32(8):1034-1044. PubMed ID: 33932507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]